Hot Features
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Pha... Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.003 | -0.769230769231 | 0.39 | 0.4435 | 0.383 | 1799257 | 0.41203883 | DE |
| 4 | -0.019 | -4.67980295567 | 0.406 | 0.4435 | 0.3815 | 1525731 | 0.40586278 | DE |
| 12 | -0.183 | -32.1052631579 | 0.57 | 0.77 | 0.328 | 2845942 | 0.46861611 | DE |
| 26 | 0.081 | 26.4705882353 | 0.306 | 0.77 | 0.273 | 2301893 | 0.40969809 | DE |
| 52 | -0.003 | -0.769230769231 | 0.39 | 0.77 | 0.273 | 1434031 | 0.40164083 | DE |
| 156 | 0.089 | 29.8657718121 | 0.298 | 1.04 | 0.1544 | 496335 | 0.41741151 | DE |
| 260 | -1.653 | -81.0294117647 | 2.04 | 2.29 | 0.1544 | 317190 | 0.46997227 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.